221121-65-9

Upstream product

• 17356-08-0 thiourea 
• 221121-46-6 ethyl 4-(2,6-difluorophenyl)-3-oxobutanoate 
• 221121-33-1 2-(2,6-difluoro-phenyl)-1-imidazol-1-yl-ethanone 

Downstream Products

• 221122-02-7 6-(2,6-difluoro-benzyl)-2-isopropylsulfanyl-3H-pyrimidin-4-one 
• 221122-06-1 2-cyclopentylthio-6-(2,6-difluorophenylmethyl)-3,4-dihydrogyrimidin-4-(3H)-one 
• 221122-05-0 2-sec-butylsulfanyl-6-(2,6-difluoro-benzyl)-3H-pyrimidin-4-one 
• 221122-04-9 6-(2,6-difluoro-benzyl)-2-isobutylsulfanyl-3H-pyrimidin-4-one 
• 221122-07-2 2-cyclohexylsulfanyl-6-(2,6-difluoro-benzyl)-3H-pyrimidin-4-one 
• 221122-01-6 6-(2,6-difluorophenylmethyl)-3,4-dihydro-2-methylthiopyrimidin-4(3H)-one 

Relevant academic research and scientific papers

Does the 2-methylthiomethyl substituent really confer high anti-HIV-1 activity to S-DABOs?

S-DABO derivatives containing the methylthiomethyl (MTM) group have been synthesized and tested for anti-HIV-1 activity in cell-based assay (MTT and p24 assays) and for their capability to target the HIV-1 reverse transcriptase in enzyme assays. Data of experiments lead to the conclusion that the introduction of a 2-MTM-thio side chain is not sufficient per se to significantly increase S-DABO's potency. Nevertheless, potent MTM-S-DABOs can be obtained by introducing a 2,6-difluorophenylmethyl moiety as a C-6 substituent.

5-alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin- 4(3H)-ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives

Molecular modeling analysis of compounds belonging to the recently published series of dihydro-alkoxy-benzyl-oxopyrimidines (DABOs), such as S- DABOs and DATNOs, gave support to the design of new 2,6-disubstituted benzyl- DABO derivatives as highly potent